Hemophilia B is an X-linked recessive disorder characterized by a deficiency in coagulation factor IX (FIX), leading to spontaneous or trauma-induced bleeding episodes with significant morbidity and mortality if untreated. Traditional plasma-derived FIX concentrates, while effective, posed risks of bloodborne pathogen transmission. The advent of recombinant FIX products, such as BeneFIX in 1997, offered a safer alternative. Alprolix, a long-acting recombinant FIX product approved in 2014, employs Fc fusion technology to extend the half-life of FIX, reducing dosing frequency and enhancing patient convenience. This review delves into the protein synthesis technologies behind FIX preparations, with a focus on recombinant methods, and evaluates the current state of recombinant FIX therapy. Alprolix is administered intravenously and has shown good tolerability, efficacy, and no inhibitors in clinical trials, indicating its safety. Pharmacokinetic studies reveal a half-life of approximately 82.1 hours, supporting less frequent dosing. The volume of distribution, area under the curve, clearance rate, and elimination rate constant are detailed, highlighting Alprolix’s extended duration and therapeutic goal of maintaining stable clotting factor IX levels. Alprolix’s performance in preventive treatment, with a zero annualized spontaneous bleeding rate in children, underscores its role in reducing joint bleeding and disability rates. Despite advancements, challenges in treatment optimization and global accessibility persist. This paper seeks to highlight potential future directions for improving hemophilia B treatment, emphasizing the need for further innovations in stability, efficacy, and accessibility of advanced therapies.
